Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Mikus

Showing results (61-70 of 194) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|February 21, 2014
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosingMichael J Dolton, Gerd Mikus, Johanna Weiss, et al.
Therapeutic Drug Monitoring|May 29, 2007
The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humansLisa Dietz, Anna Glaz-Sandberg, Hang Nguyen, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2007
Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medicationsMarcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, et al.
European Journal of Pharmacology|June 25, 2025
In vitro and in silico evaluation of the interaction of yohimbine with drug transporters and cytochrome P450 isoenzymesGzona Bajraktari-Sylejmani, Rajamanikkam Kamaraj, Petr Pavek, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 15, 2016
Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosingLukas Witt, Yosuke Suzuki, Nicolas Hohmann, et al.
Journal of Clinical Pharmacology|September 25, 2020
Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure TimeJana Grass, Peter Rose, Jürgen Burhenne, et al.
British Journal of Clinical Pharmacology|June 22, 2019
Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdosesNicolas Hohmann, Antje Blank, Jürgen Burhenne, et al.
British Journal of Clinical Pharmacology|December 24, 2010
The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myelomaGerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, et al.
British Journal of Clinical Pharmacology|January 16, 2015
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humansNicolas Hohmann, Franziska Kocheise, Alexandra Carls, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjectsA Glaz-Sandberg, L Dietz, H Nguyen, et al.
Pageof 20

Showing results (61-70 of 194) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|February 21, 2014
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosingMichael J Dolton, Gerd Mikus, Johanna Weiss, et al.
Therapeutic Drug Monitoring|May 29, 2007
The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humansLisa Dietz, Anna Glaz-Sandberg, Hang Nguyen, et al.
Antimicrobial Agents and Chemotherapy|July 4, 2007
Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medicationsMarcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, et al.
European Journal of Pharmacology|June 25, 2025
In vitro and in silico evaluation of the interaction of yohimbine with drug transporters and cytochrome P450 isoenzymesGzona Bajraktari-Sylejmani, Rajamanikkam Kamaraj, Petr Pavek, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 15, 2016
Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosingLukas Witt, Yosuke Suzuki, Nicolas Hohmann, et al.
Journal of Clinical Pharmacology|September 25, 2020
Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure TimeJana Grass, Peter Rose, Jürgen Burhenne, et al.
British Journal of Clinical Pharmacology|June 22, 2019
Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdosesNicolas Hohmann, Antje Blank, Jürgen Burhenne, et al.
British Journal of Clinical Pharmacology|December 24, 2010
The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myelomaGerlinde Egerer, Kathrin Eisenlohr, Martina Gronkowski, et al.
British Journal of Clinical Pharmacology|January 16, 2015
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humansNicolas Hohmann, Franziska Kocheise, Alexandra Carls, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjectsA Glaz-Sandberg, L Dietz, H Nguyen, et al.
Pageof 20